Effects of Ulinastatin combined with Octreotide in treatment of patients with severe acute pancreatitis
Objective:To observe effects of Ulinastatin combined with Octreotide in treatment of patients with severe acute pancreatitis(SAP).Methods:A prospective study was conducted on 100 patients with SAP admitted to this hospital from January 2021 to January 2023.They were divided into control group and study group according to the random number table method,50 cases in each.The control group was treated with Octreotide acetate injection,while the study group was treated with Ulinastatin injection on the basis of that of the control group.The clinical efficacy,the inflammatory factors[C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]levels before and after the treatment,the blood and urine amylase levels,the immunoglobulin index levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 98.00%(49/50),which was higher than 80.00%(40/50)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CRP,TNF-α and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of blood and urine amylase in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of IgA,IgM and IgG in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ulinastatin combined with Octreotide in the treatment of the SAP patients can improve the treatment effects and the immunoglobulin index levels and reduce the blood and urine amylase and inflammatory factor levels.Moreover,it is superior to single Octreotide treatment.
Severe acute pancreatitisUlinastatinOctreotideInflammatory factorAmylaseImmunoglobulinAdverse reaction
万方数据
维普
